Interleukin 2 receptor antagonists for kidney transplant recipients

Angela C. Webster, Elliott Geoffrey Playford, Gail Y. Higgins, Jeremy R Chapman, Jonathan C. Craig

Research output: Contribution to journalArticlepeer-review

126 Citations (Scopus)


Acute rejection is a major problem in the early period following kidney transplantation. Immunosuppressive drugs are used to prevent this. IL2Ra, a new class antibody therapy, can be added to a patient's existing immunosuppression to further reduce the risk of rejection. This review found that IL2Ra reduced the risk of acute rejection at six and 12 months after kidney transplantation but did not improve kidney or patient survival. IL2Ra treatment had fewer side effects than other antibody therapy.
Original languageEnglish
Article numberCD003897
JournalCochrane Database of Systematic Reviews
Issue number1
Publication statusPublished - 26 Jan 2004
Externally publishedYes


  • kidney transplantation
  • recipients
  • Rejection


Dive into the research topics of 'Interleukin 2 receptor antagonists for kidney transplant recipients'. Together they form a unique fingerprint.

Cite this